Hyperthermia Cancer Treatment Market Global Report 2026

The hyperthermia cancer treatment market size has grown strongly in recent years. It will grow from $0.29 billion in 2025 to $0.31 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising global cancer prevalence rates, increasing adoption of radiation and chemotherapy treatments, growth in hospital oncology infrastructure, expansion of clinical research in cancer therapies, and increasing awareness of advanced cancer treatment options.

The hyperthermia cancer treatment market size is expected to see strong growth in the next few years. It will grow to $0.41 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising demand for precision oncology and personalized treatment approaches, increasing adoption of combination cancer therapies, growth in non-invasive and targeted treatment technologies, expansion of healthcare infrastructure in emerging economies, and increasing investment in medical device innovation for cancer care. Major trends in the forecast period include increasing adoption of image-guided hyperthermia treatment systems for precise tumor targeting, rising integration of AI-based treatment planning for optimized thermal dose delivery, growth in combination therapies using hyperthermia with radiation and chemotherapy, expansion of minimally invasive and localized cancer heating techniques, and increasing use of real-time temperature monitoring and feedback control systems in oncology treatment.

The rising global cancer incidence is expected to drive the growth of the hyperthermia cancer treatment market in the coming years. Cancer incidence refers to the number of newly diagnosed cancer cases within a specific population over a defined time period. The increase in global cancer incidence is mainly attributed to population aging, as longer life expectancy leads to a higher proportion of individuals reaching ages where cancer risk is significantly elevated. Hyperthermia cancer treatment supports cancer care by improving tumor sensitivity to conventional therapies such as radiation and chemotherapy while also reducing systemic toxicity and side effects. For instance, in October 2025, according to the National Library of Medicine, a US-based government agency, global cancer incidence is expected to rise by 60.7% between 2024 and 2050, increasing from 19 million new cases to 30.5 million cases over the forecast period. Therefore, the rising global cancer incidence is driving the growth of the hyperthermia cancer treatment market.

Major companies operating in the hyperthermia cancer treatment market are focusing on developing advanced solutions such as AI-assisted image-guided thermal targeting platforms to enhance precision tumor heating through real-time imaging feedback and controlled thermal dose delivery. AI-assisted image-guided thermal targeting platforms refer to systems that integrate artificial intelligence with real-time medical imaging to accurately guide and regulate therapeutic heat delivery to targeted tissues, thereby improving treatment precision and safety. For instance, in March 2026, New Phase Ltd., an Israel-based medical technology company, introduced the SARAH Nanoparticle Electromagnetic Hyperthermia Platform, which facilitates targeted tumor heating up to 50°C using magnetically activated nanoparticles under electromagnetic induction. It improves selective cancer cell destruction while preserving healthy tissue integrity and offers a non-invasive, repeatable treatment approach with reduced systemic toxicity compared to conventional chemotherapy and radiation therapy.

In February 2026, Mayo Clinic, a US-based medical research and healthcare institution, partnered with New Phase Ltd. to advance early-stage clinical research. Through this collaboration, Mayo Clinic aims to support early-stage clinical evaluation and validation of nanoparticle-based electromagnetic hyperthermia therapy for advanced-stage cancers, while assessing its safety, tumor-targeting efficiency, and potential to improve patient outcomes compared to conventional oncology treatments, thereby supporting the development of next-generation hyperthermia cancer treatment technologies. New Phase Ltd. is an Israel-based medical technology company specializing in nanoparticle-based electromagnetic hyperthermia systems for cancer therapy.

Major companies operating in the hyperthermia cancer treatment market are Chongqing Haifu Medical Technology Co. Ltd, InSightec Ltd., Profound Medical Corp., FocalTherics, Yamamoto Vinita Co. Ltd., Pyrexar Medical Inc., Sonablate Corp., Oncotherm Kft, Celsius42 GmbH, Clinical Laserthermia Systems AB, Theraclion SA, RanD S.r.l., Combat Medical Ltd., Sensius B.V., Dr. Sennewald Medizintechnik GmbH, Med-Logix SRL, Heckel Medizintechnik GmbH, Hydrosun GmbH, Therma Solutions Inc., Elmedical Ltd., NovaFlux Technologies, ThermaMed GmbH.

North America was the dominant region in the hyperthermia cancer treatment market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in hyperthermia cancer treatment report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperthermia cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hyperthermia cancer treatment market consists of revenues earned by entities by providing services such as localized hyperthermia therapy for tumor treatment, whole-body hyperthermia, combination therapy with radiotherapy or chemotherapy, treatment planning, and temperature monitoring during therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperthermia cancer treatment market also includes sales of deep regional hyperthermia systems, interstitial hyperthermia applicators, endocavity hyperthermia applicators, and thermal therapy probes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The hyperthermia cancer treatment market research report is one of a series of new reports that provides hyperthermia cancer treatment market statistics, including hyperthermia cancer treatment industry global market size, regional shares, competitors with a hyperthermia cancer treatment market share, detailed hyperthermia cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperthermia cancer treatment industry. This hyperthermia cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.